BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 28772071)

  • 1. Systemic Delivery of Folate-PEG siRNA Lipopolyplexes with Enhanced Intracellular Stability for In Vivo Gene Silencing in Leukemia.
    Lee DJ; Kessel E; Lehto T; Liu X; Yoshinaga N; Padari K; Chen YC; Kempter S; Uchida S; Rädler JO; Pooga M; Sheu MT; Kataoka K; Wagner E
    Bioconjug Chem; 2017 Sep; 28(9):2393-2409. PubMed ID: 28772071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folate receptor-directed orthogonal click-functionalization of siRNA lipopolyplexes for tumor cell killing in vivo.
    Klein PM; Kern S; Lee DJ; Schmaus J; Höhn M; Gorges J; Kazmaier U; Wagner E
    Biomaterials; 2018 Sep; 178():630-642. PubMed ID: 29580727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual antitumoral potency of EG5 siRNA nanoplexes armed with cytotoxic bifunctional glutamyl-methotrexate targeting ligand.
    Lee DJ; Kessel E; Edinger D; He D; Klein PM; Voith von Voithenberg L; Lamb DC; Lächelt U; Lehto T; Wagner E
    Biomaterials; 2016 Jan; 77():98-110. PubMed ID: 26584350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumoral gene silencing by receptor-targeted combinatorial siRNA polyplexes.
    Lee DJ; He D; Kessel E; Padari K; Kempter S; Lächelt U; Rädler JO; Pooga M; Wagner E
    J Control Release; 2016 Dec; 244(Pt B):280-291. PubMed ID: 27287890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-PEGylation of siRNA Lipo-oligoamino Amide Polyplexes Using Tetra-glutamylated Folic Acid as Ligand for Receptor-Targeted Delivery.
    Müller K; Kessel E; Klein PM; Höhn M; Wagner E
    Mol Pharm; 2016 Jul; 13(7):2332-45. PubMed ID: 27177200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient and Tumor Targeted siRNA Delivery by Polyethylenimine-graft-polycaprolactone-block-poly(ethylene glycol)-folate (PEI-PCL-PEG-Fol).
    Liu L; Zheng M; Librizzi D; Renette T; Merkel OM; Kissel T
    Mol Pharm; 2016 Jan; 13(1):134-43. PubMed ID: 26641134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zwitterionic Nanocarrier Surface Chemistry Improves siRNA Tumor Delivery and Silencing Activity Relative to Polyethylene Glycol.
    Jackson MA; Werfel TA; Curvino EJ; Yu F; Kavanaugh TE; Sarett SM; Dockery MD; Kilchrist KV; Jackson AN; Giorgio TD; Duvall CL
    ACS Nano; 2017 Jun; 11(6):5680-5696. PubMed ID: 28548843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Native chemical ligation for conversion of sequence-defined oligomers into targeted pDNA and siRNA carriers.
    Zhang CY; Kos P; Müller K; Schrimpf W; Troiber C; Lächelt U; Scholz C; Lamb DC; Wagner E
    J Control Release; 2014 Apr; 180():42-50. PubMed ID: 24566255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipidation of polyethylenimine-based polyplex increases serum stability of bioengineered RNAi agents and offers more consistent tumoral gene knockdown in vivo.
    Zhang QY; Ho PY; Tu MJ; Jilek JL; Chen QX; Zeng S; Yu AM
    Int J Pharm; 2018 Aug; 547(1-2):537-544. PubMed ID: 29894758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. pH-responsive complexes using prefunctionalized polymers for synchronous delivery of doxorubicin and siRNA to cancer cells.
    Dong DW; Xiang B; Gao W; Yang ZZ; Li JQ; Qi XR
    Biomaterials; 2013 Jul; 34(20):4849-59. PubMed ID: 23541420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. pH-responsive hybrid quantum dots for targeting hypoxic tumor siRNA delivery.
    Zhu H; Zhang S; Ling Y; Meng G; Yang Y; Zhang W
    J Control Release; 2015 Dec; 220(Pt A):529-544. PubMed ID: 26590349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-delivery of pretubulysin and siEG5 to EGFR overexpressing carcinoma cells.
    Truebenbach I; Zhang W; Wang Y; Kern S; Höhn M; Reinhard S; Gorges J; Kazmaier U; Wagner E
    Int J Pharm; 2019 Oct; 569():118570. PubMed ID: 31352048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimized polyethylenimine (PEI)-based nanoparticles for siRNA delivery, analyzed in vitro and in an ex vivo tumor tissue slice culture model.
    Ewe A; Höbel S; Heine C; Merz L; Kallendrusch S; Bechmann I; Merz F; Franke H; Aigner A
    Drug Deliv Transl Res; 2017 Apr; 7(2):206-216. PubMed ID: 27334279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination antitumor immunotherapy with VEGF and PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells.
    Song Y; Tang C; Yin C
    Biomaterials; 2018 Dec; 185():117-132. PubMed ID: 30241030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts.
    Yoshizawa T; Hattori Y; Hakoshima M; Koga K; Maitani Y
    Eur J Pharm Biopharm; 2008 Nov; 70(3):718-25. PubMed ID: 18647651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-delivery of Bmi1 small interfering RNA with ursolic acid by folate receptor-targeted cationic liposomes enhances anti-tumor activity of ursolic acid
    Li W; Yan R; Liu Y; He C; Zhang X; Lu Y; Khan MW; Xu C; Yang T; Xiang G
    Drug Deliv; 2019 Dec; 26(1):794-802. PubMed ID: 31366257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: for the potential targeted ovarian cancer gene therapy.
    Li TS; Yawata T; Honke K
    Eur J Pharm Sci; 2014 Feb; 52():48-61. PubMed ID: 24178005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a targeted siRNA delivery system using FOL-PEG-PEI conjugate.
    Biswal BK; Debata NB; Verma RS
    Mol Biol Rep; 2010 Jul; 37(6):2919-26. PubMed ID: 19816791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combinatorial siRNA Polyplexes for Receptor Targeting.
    Lee DJ; Wagner E
    Methods Mol Biol; 2019; 1974():83-98. PubMed ID: 31098997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted decationized polyplexes for siRNA delivery.
    Novo L; Takeda KM; Petteta T; Dakwar GR; van den Dikkenberg JB; Remaut K; Braeckmans K; van Nostrum CF; Mastrobattista E; Hennink WE
    Mol Pharm; 2015 Jan; 12(1):150-61. PubMed ID: 25384057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.